Cedar Knolls, NJ (PRWEB) December 23, 2005
Xybion Medical Systems Corporation (Xybion), a developer, and supplier of comprehensive preclinical data management systems announced today that one of its newest clients is the first to complete internal testing of PATH/TOX SYSTEM and has placed the system into production for acute studies – in record time of four months from delivery.
PATH/TOX SYSTEM is a suite of tightly integrated functions that addresses all aspects of preclinical data acquisition, management, and reporting. Clients have the flexibility to license only those functions and options needed to support their study protocols and processes.
“This is a major milestone achievement and is a great way to cap off a successful and exciting year,” said David M. Neglia, Xybion’s Chief Executive Officer, and President. “We are very pleased with the success our new system has been achieving in the market; as evidenced by the recent addition of three new client companies who rank in the Top 20 in pharmaceutical sales worldwide. These clients represent the addition of over nine hundred licensed users and eight new facilities to our user community.”
Xybion’s products are industry leaders and are used by the world’s largest and most prestigious pharmaceutical and contract research companies to assess compound safety while reducing time to market.
# # #